All News

Will 2011 be the year that medical malpractice reform becomes a reality? The new political alignment in Congress appears to offer more hope than in many years past, and advocates are anxious to achieve that long-elusive objective.

Results of a phase III trial failed to confirm data from a phase II study suggesting that the addition of high-dose oral calcitriol (DN-101) to docetaxel (Taxotere) confers a survival advantage and reduces toxicity versus treatment with docetaxel alone in men with progressive castration-resistant prostate cancer (CRPC).

Physical activity is associated with a lower risk of overall mortality and death due to prostate cancer, say researchers from the Harvard School of Public Health, Boston, and the University of California, San Francisco.

National Government Services (NGS), a regional Medicare carrier, recently issued a future negative coverage decision on posterior tibial nerve stimulation therapy (Urgent PC, Uroplasty, Inc., Minneapolis) that became effective in four states after Jan. 3, 2011.

Congress passed a bill in December that exempts physicians, nurse practitioners, and non-medical professionals from the Federal Trade Commission?s ?Red Flags Rule,? which helps protect consumers from identity theft.

Centocor Ortho Biotech Inc. has submitted a new drug application to the FDA for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane.

The Centers for Medicare & Medicaid Services and the Office of the National Coordinator for Health Information Technology recently announced the availability of registration for Medicare and Medicaid electronic health record incentive programs.

Urologists and other physicians who treat Medicare patients have again escaped a steep reimbursement reduction as President Obama on Dec. 15 signed legislation passed by the lame-duck Congress providing a 12-month reprieve.

For the management of refractory urge incontinence, non-pharmacologic options can be used alone or in combination with anticholinergic medications will be adequate treatment for many patients, but some will need further therapy.

While it is tempting to look only at "the bottom line," the contemporary physician manager/owner needs to have a more thorough understanding of the numbers that contribute to that bottom line and how to use that information to quickly discover problems and solutions.

We no longer need to consider if laparoendoscopic single-site surgery is safe and effective-with the caveat of experienced hands-but we do need to examine in whom the cosmetic advantages of LESS merit the added surgical complexity.